What can we learn from the SARS-COV-2 pandemic about the value of specific radiological examinations?

被引:5
|
作者
Hofmann, Bjorn [1 ,2 ]
Andersen, Eivind Richter [1 ]
Kjelle, Elin [1 ]
机构
[1] Norwegian Univ Sci & Technol NTNU Gjovik, Inst Hlth Sci, POB 191, N-2802 Gjovik, Norway
[2] Univ Oslo, Ctr Med Eth, Oslo, Norway
关键词
Low-value care; Appropriateness; Choosing wisely; Ethics; Covid-19; SARS-COV-2; MEDICAL-CARE; COVID-19; OVERUSE;
D O I
10.1186/s12913-021-07190-w
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background The SARS-COV-2 pandemic provides a natural intervention to assess practical priority setting and internal evaluation of specific health services, such as radiological services. Norway makes an excellent case as it had a very low infection rate and very few cases of COVID-19. Accordingly, the objective of this study is to use the changes in performed outpatient radiological examinations during the first stages of the SARS-COV-2 pandemic to assess the practical evaluation of specific radiological examinations in Norway. Methods Data was collected retrospectively from the Norwegian Health Economics Administration (HELFO) in the years 2015-2020. Data included the number of performed outpatient imaging examinations at public hospitals and private imaging centers in Norway and was divided in to three periods based on the level of restrictions on elective health services. Results were analyzed with descriptive statistics. Results In the first period there was a 45% reduction in outpatient radiology compared to the same time period in 2015-2019 while in period 2 and 3 there was a 25 and 6% reduction respectively. The study identified a list of specific potential low-value radiological examinations. While some of these are covered by the Choosing Wisely campaign, others are not. Conclusion By studying the priority setting practice during the initial phases of the pandemic this study identifies a set of potential low value radiological examinations during the initial phases of the SARS-COV-2 pandemic. These examinations are candidates for closer assessments for health services quality improvement.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] What do we know about the function of SARS-CoV-2 proteins?
    Arevalo, Santiago Justo
    Castillo-Chavez, Adriana
    Calampa, Carmen Sofia Uribe
    Sifuentes, Daniela Zapata
    Huallpa, Cesar J.
    Bianchi, Gianfranco Landa
    Casas, Romina Garavito-Salini
    Aguilar, Mauro Quinones
    Chavarria, Roberto Pineda
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [22] What do we know about the SARS-CoV-2 coronavirus in the environment?
    Nunez-Delgado, Avelino
    [J]. SCIENCE OF THE TOTAL ENVIRONMENT, 2020, 727
  • [23] The SARS-CoV-2 pandemic and asthma: What we have learned and what is still unknown
    Mcphee, Christa
    Yevdokimova, Kateryna
    Rogers, Linda
    Kraft, Monica
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 152 (06) : 1376 - 1381
  • [24] Safer Singing During the SARS-CoV-2 Pandemic: What We Know and What We Don't
    Naunheim, Matthew R.
    Bock, Jonathan
    Doucette, Philip A.
    Hoch, Matthew
    Howell, Ian
    Johns, Michael M.
    Johnson, Aaron M.
    Krishna, Priya
    Meyer, David
    Milstein, Claudio F.
    Nix, John
    Pitman, Michael J.
    Robinson-Martin, Trineice
    Rubin, Adam D.
    Sataloff, Robert T.
    Sims, Herbert Steven
    Titze, Ingo R.
    Carroll, Thomas L.
    [J]. JOURNAL OF VOICE, 2021, 35 (05) : 765 - 771
  • [25] Post-Viral Olfactory Loss: What We Learned from the SARS-CoV-2 Pandemic
    Vaira, Luigi Angelo
    Deiana, Giovanna
    Maglitto, Fabio
    Salzano, Giovanni
    [J]. LIFE-BASEL, 2022, 12 (11):
  • [26] Wearables in the SARS-CoV-2 Pandemic: What Are They Good for?
    Bent, Brinnae
    Dunn, Jessilyn P.
    [J]. JMIR MHEALTH AND UHEALTH, 2020, 8 (12):
  • [27] Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?
    Reinhart Speeckaert
    Jo Lambert
    Luis Puig
    Marijn Speeckaert
    Hilde Lapeere
    Sofie De Schepper
    Nanja van Geel
    [J]. Drugs in R&D, 2021, 21 : 341 - 350
  • [28] Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?
    Speeckaert, Reinhart
    Lambert, Jo
    Puig, Luis
    Speeckaert, Marijn
    Lapeere, Hilde
    De Schepper, Sofie
    van Geel, Nanja
    [J]. DRUGS IN R&D, 2021, 21 (03) : 341 - 350
  • [29] The SARS-CoV-2 outbreak: What we know
    Wu, Di
    Wu, Tiantian
    Liu, Qun
    Yang, Zhicong
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 94 : 44 - 48
  • [30] SARS-CoV-2 in animals: what about the cat?
    Teixeira, Ana Izabel Passarella
    [J]. VETERINARY QUARTERLY, 2021, 41 (01) : 226 - 227